Pieter V. D. B.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- Phase III Comparative Study of Docetaxel Versus Docetaxel Plus Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer
- Evaluation of Shortened 12-Month Androgen Receptor Signaling Inhibitor Therapy with Androgen Deprivation in Low-Volume Metastatic Castration-Sensitive Prostate Cancer
Data & Insights
Has run more than one trial at 162 of 349 partner sites.
Specializations
Prostate Cancer Therapeutics
The investigator specializes in treating advanced forms of prostate cancer, with particular focus on metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).
- Hormone Therapy Innovations
- Novel Drug Combinations
- Targeted Therapies
Their research encompasses various therapeutic approaches including hormone therapy agents and innovative drug combinations.
Precision Medicine Approaches
The investigator focuses on personalized treatment strategies, particularly in PTEN-deficient prostate cancers and targeted therapeutic interventions.
- Biomarker-Driven Treatments
- Molecular Targeting
- Genetic Profiling
Their work includes evaluation of novel compounds and targeted therapies for specific genetic mutations.
Advanced Treatment Modalities
The investigator explores combination approaches incorporating radiopharmaceuticals and chemotherapy for advanced prostate cancer treatment.
- Combination Therapies
- Radiopharmaceutical Applications
- Treatment Sequencing
Their research includes innovative therapeutic combinations aimed at improving survival outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.